Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3302 |
Name | chordoma |
Definition | A notochordal cancer that derives_from cellular remnants of the notochord. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer bone cancer notochordal cancer chordoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
CDKN2A loss | Palbociclib | chordoma | sensitive | detail... |
CDKN2A loss | Abemaciclib | chordoma | sensitive | detail... |
SMARCB1 negative | Tazemetostat | chordoma | predicted - sensitive | detail... |
MLH1 negative | Pembrolizumab | chordoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | chordoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01407198 | Phase I | Nilotinib | Nilotinib With Radiation for High Risk Chordoma | Active, not recruiting | USA | 0 |
NCT02383498 | Phase II | GI-6301 | The National Cancer Institute Opens A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma | Completed | USA | 0 |
NCT02389244 | Phase II | Regorafenib | A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) | Recruiting | FRA | 0 |
NCT02601950 | Phase II | Tazemetostat | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | Completed | USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS | 1 |
NCT02989636 | Phase I | Nivolumab | Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma | Active, not recruiting | USA | 0 |
NCT03083678 | Phase II | Afatinib | Afatinib in Locally Advanced and Metastatic Chordoma | Unknown status | NLD | ITA | GBR | 0 |
NCT03110744 | Phase II | Palbociclib | CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma (NCT-PMO-1601) | Completed | DEU | 0 |
NCT03173950 | Phase II | Nivolumab | Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers | Recruiting | USA | 0 |
NCT03623854 | Phase II | Nivolumab + Relatlimab | Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma | Completed | USA | 0 |
NCT03647423 | Phase Ib/II | Aldoxorubicin + Avelumab + Cetuximab + ETBX-051 + ETBX-061 + GI-6301 + haNK cells + Nogapendekin alfa inbakicept | QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. | Withdrawn | USA | 0 |
NCT03886311 | Phase II | Nivolumab + Talimogene laherparepvec + Trabectedin | Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (TNT) | Recruiting | USA | 0 |
NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Completed | USA | 0 |
NCT04246671 | Phase Ib/II | TAEK-VAC-HerBy Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab | TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer | Active, not recruiting | USA | 0 |
NCT04416568 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | Recruiting | USA | 0 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT04741438 | Phase III | Ipilimumab + Nivolumab Pazopanib | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) | Recruiting | FRA | 0 |
NCT04965753 | Phase I | FHD-609 | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | Terminated | USA | ITA | FRA | ESP | 0 |
NCT05041127 | Phase II | Cetuximab | Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma | Recruiting | USA | 0 |
NCT05286801 | Phase Ib/II | Atezolizumab + Tiragolumab | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT05407441 | Phase Ib/II | Ipilimumab + Nivolumab + Tazemetostat | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | Recruiting | USA | 0 |